

ASIT biotech postpones the publication of its 2019 annual report

Liège, Belgium, 3 May 2020, 6.00 pm (CEST) – ASIT biotech (ASIT - BE0974289218), a biopharmaceutical company focused on the research and development of breakthrough immunotherapy, announces that it is postponing to May 7, 2020 the publication of its 2019 annual report in accordance with government measures adopted due to the COVID-19 crisis. The ordinary general meeting should however be held at the date provided for in the company's articles of association, namely June 11, 2020.

About ASIT biotech

ASIT biotech is a Belgian clinical stage biopharmaceutical company focused on the development and future commercialization of a range of breakthrough immunotherapy products for the treatment of allergies. Thanks to its innovative ASIT+™ technology platform, ASIT biotech is currently the only developer of allergy immunotherapy (AIT) product candidates consisting of a unique mixture of highly purified natural allergen fragments in an optimal size selection. This innovation results in a short treatment, expected to improve patient compliance and real-life effectiveness.

Further information can be found at www.asitbiotech.com.

Follow us on LinkedIn

Company contact

Michel Baijot, CEO
ASIT biotech
Tel.: +32 2 264 03 90
investors@asitbiotech.com

Legal notice

This announcement is for information purposes only and does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for the Company's shares in any jurisdiction. This announcement does not constitute a prospectus. Any purchase of, subscription for or application for, Shares to be issued in connection with the intended offering should only be made on the basis of information contained in the prospectus and any supplements thereto, as the case may be.

Forward-looking statements

This release may contain forward-looking statements. Such forward-looking statements are not guaranteeing future results. These forward-looking statements speak only as of the date of publication of this document. The Company expressly disclaims any obligation to update any forward-looking statements in this document, unless specifically required by law or regulation.

Important information

This press release is a translation of the original press release in French. In case of differences in translation or interpretation, it is the original press release in French who will prevail.